HBx inhibits p53-mediated activation of miR-148a, whose expression is downregulated in HBV-related HCC patients and exhibits a negative correlation with Hematopoietic pre-B cell leukemia transcription factor-interacting protein(HPIP). Here, TP53 is linked to hepatocellular carcinoma.